- Rapidly expanding multi-national network infrastructure delivers on Abdul Latif Jameel Health promise of accelerating access to modern medical care across the global south
Dubai, UAE: Abdul Latif Jameel Health, part of international diversified family business Abdul Latif Jameel, has announced the creation of its new international commercial channel, helping to accelerate access to modern medical care and drive health inclusivity across the Global South.
The network of confirmed partners will cover key markets across a wide geographic area including India, Kuwait, Morocco, Oman, Saudi Arabia, Turkey and the UAE, and will see on the ground distribution of Abdul Latif Jameel Health approved products into hospitals, clinics and medical institutions to fast-track health inclusion for those who need it most. Abdul Latif Jameel Health is continuing contractual negotiations for partnerships and acquisitions with other important markets and the network will grow over the coming months across Africa, South and Southeast Asia, and Latin America.
Since its launch in 2020, Abdul Latif Jameel Health has developed strong relationships with renowned health partners utilizing innovation and industry disruptive approaches to deliver healthcare in more efficient ways. Partners include Butterfly Network, EQRx, Cyberdyne, Evelo Biosciences, Melody International and Holoeyes Inc., among others.
Akram Bouchenaki, Chief Executive Officer, Abdul Latif Jameel Health said: “The Global South covers a huge geographical area with nations that are diverse and complex, both commercially and culturally. It is for this reason that it is so important we work with partners who understand their markets intrinsically and can align with the respective regulatory authorities for our range of products and services we are delivering.
“At Abdul Latif Jameel Health, we are delivering on our promise of offering an integrated ‘one-stop’ managed service to medical devices, pharmaceutical products, diagnostic and therapeutics manufacturers to afford them multi-market access more rapidly than they could manage individually. We will distribute their products to the populations that can most benefit from them sooner, meeting unmet medical needs, driving healthcare inclusivity, and in parallel, opening the unrealized commercial potential of these markets.”
Last month, Abdul Latif Jameel Health also announced the appointment of three globally respected and renowned scientists as special scientific advisors to join its mission in accelerating access to modern medical care across the Global South. The advisors are: The Right Hon. Professor Lord Kakkar PC, Director of the Thrombosis Research Institute and Emeritus Professor of Surgery at University College London; Professor James J. Collins, PhD, Termeer Professor of Medical Engineering and Science at the Institute for Medical Engineering & Science (IMES) and Department of Biological Engineering at the Massachusetts Institute of Technology (MIT) and Founder of the Jameel Clinic at MIT; and Professor Charles Coombes, PhD MBBS FRCP MD FMedSci, Professor of Medical Oncology, Imperial College London.
Abdul Latif Jameel Health was created in 2020 as a response to the ongoing global disparity in access to modern medical care, focusing on accelerating healthcare inclusion across the Global South. Reflecting the Jameel Family’s long-established commitment to innovating for a better future, Abdul Latif Jameel Health works in the commercial environment to address tangible real-world needs today, for a better tomorrow. It works with partners from around the world to open and grow new markets for distribution of existing solutions and investing in the future of MedTech.
About Abdul Latif Jameel Health
Backed by Abdul Latif Jameel, one of the most respected diversified family businesses and investors with a 75-year heritage, deep roots, and established networks alongside a multi-sector presence in 30 countries across six continents, Abdul Latif Jameel Health is uniquely positioned as a trusted partner in realizing major innovations and opportunities in the healthcare world.
Abdul Latif Jameel Health reflects the Jameel family’s long-established commitment to innovating for a better future through Community Jameel, an international organization supporting science and technology-led solutions to global challenges. Community Jameel and MIT co-founded the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) in September 2018 – which has rapidly become the very epicenter of AI and healthcare at MIT – and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (Jameel Institute) co-founded with Imperial College London, in October 2019, using novel data analytics to reduce global risk of preventable disease most recently including the 2020 COVID-19 pandemic, and strengthening health systems in the most fragile settings.
Abdul Latif Jameel Health takes this commitment into the commercial environment addressing tangible real-world needs today, for a better tomorrow. It is focused on health care inclusion in the global south, accelerating access to modern medical care for those who need it most by opening up/growing new markets for distribution of existing solutions and investing in the future of MedTech.
The Jameel Investment Management Company (JIMCO) , actively invests in innovative, early-stage and breakthrough ventures and technology, aiming to positively shape the future of core industries driving the global economy through its’ investments that span medical and healthcare industries, from pharmaceuticals and vaccines to cutting-edge medical technology, along with emergent technologies across FinTech, InsurTech, electric vehicles and future mobility solutions.
For further information, visit: https://aljhealth.com and our brand video here.
Media Contact: Email firstname.lastname@example.org
Copyright Notice and Disclaimer
© Meddist Company Ltd. (Abdul Latif Jameel Health). All rights fully reserved. The Abdul Latif Jameel name, and the Abdul Latif Jameel logotype and pentagon-shaped graphic are trademarks, or registered trademarks of Abdul Latif Jameel IPR Company Limited.
The term “Abdul Latif Jameel” refers broadly to several distinct, separate and independent legal entities. Abdul Latif Jameel is not itself a corporate entity, association or conglomerate run by an overarching parent company but merely refers to a group of distinct and wholly separate legal entities that are collectively referred to as Abdul Latif Jameel. Abdul Latif Jameel is not a corporate group as defined in section 1161(5) of the Companies Act 2006.
This document may contain forward-looking statements. Forward-looking statements are statements regarding matters other than historical fact, such as future results, events, activities, developments or circumstances or the beliefs, plans or expectations of Abdul Latif Jameel Health or Abdul Latif Jameel entities or their respective managements.
Forward-looking statements often can be identified by the use of words such as ‘expect’, ‘project’, ‘anticipate’, ‘plan’, ‘estimate’, ‘believe’, ‘predict’, ‘intend’, ‘potential’, ‘possible’, ‘probable’, ‘likely’, ‘forecast’, ‘guidance’, ‘outlook’, ‘goal’, ‘target’, ‘may’, ‘will’, ‘should’ or ‘could’ or other similar terms or phrases. However, the absence of such words does not mean that a particular statement is not forward looking.
Forward-looking statements are based on expectations and assumptions at the time of such statements and are subject to numerous risks and uncertainties, many of which are outside the control of Abdul Latif Jameel Health or Abdul Latif Jameel entities. Should any of such expectations or assumptions prove incorrect, or should any of such risks or uncertainties materialize, actual future results, events, activities, developments or circumstances may differ materially from those expressed in or implied by forward-looking statements.
Further, any forward-looking statement speaks only as of the date on which it is made, and neither Abdul Latif Jameel Health nor Abdul Latif Jameel assumes, and hereby disclaims, any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements made by Abdul Latif Jameel Health, Abdul Latif Jameel, or by any person on behalf of any of them, whether communicated in writing, electronically or orally, are qualified in their entirety by the foregoing cautionary statements.
No Offer or Solicitation
This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.